S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Aileron Therapeutics (ALRN) Stock Forecast, Price & News

0.00 (0.00%)
(As of 05/20/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
36,176 shs
Average Volume
355,419 shs
Market Capitalization
$39.96 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ALRN News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Aileron Therapeutics logo

About Aileron Therapeutics

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$0.40 per share


Net Income
$-26.16 million
Pretax Margin




Free Float
Market Cap
$39.96 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.61 out of 5 stars

Medical Sector

971st out of 1,420 stocks

Pharmaceutical Preparations Industry

482nd out of 679 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions

Is Aileron Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aileron Therapeutics stock.
View analyst ratings for Aileron Therapeutics
or view top-rated stocks.

Are investors shorting Aileron Therapeutics?

Aileron Therapeutics saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 153,600 shares, a decline of 17.0% from the April 15th total of 185,100 shares. Based on an average trading volume of 360,700 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.2% of the company's shares are short sold.
View Aileron Therapeutics' Short Interest

When is Aileron Therapeutics' next earnings date?

Aileron Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Aileron Therapeutics

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics, Inc. (NASDAQ:ALRN) issued its quarterly earnings results on Thursday, May, 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.01.
View Aileron Therapeutics' earnings history

What price target have analysts set for ALRN?

3 analysts have issued 12-month price objectives for Aileron Therapeutics' shares. Their forecasts range from $2.00 to $5.00. On average, they expect Aileron Therapeutics' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 695.5% from the stock's current price.
View analysts' price targets for Aileron Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Aileron Therapeutics' key executives?
Aileron Therapeutics' management team includes the following people:
  • Dr. Manuel C. Aivado, Pres, CEO & Director (Age 52, Pay $1.06M)
  • Mr. Richard J. Wanstall M.B.A., SVP, CFO & Treasurer (Age 53, Pay $551.69k)
  • Dr. Vojislav Vukovic M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 55, Pay $676.44k)
  • Dr. D. Allen Annis Ph.D., Sr. VP of Research (Age 49)
What other stocks do shareholders of Aileron Therapeutics own?
When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

Who are Aileron Therapeutics' major shareholders?

Aileron Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.41%), Blair William & Co. IL (1.11%), Bailard Inc. (0.14%) and Renaissance Technologies LLC (0.06%). Company insiders that own Aileron Therapeutics stock include Muneer A Satter, Reinhard J Ambros and Rickenbach Josef H Von.
View institutional ownership trends for Aileron Therapeutics

Which major investors are selling Aileron Therapeutics stock?

ALRN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., and Blair William & Co. IL.
View insider buying and selling activity for Aileron Therapeutics
or view top insider-selling stocks.

Which major investors are buying Aileron Therapeutics stock?

ALRN stock was purchased by a variety of institutional investors in the last quarter, including Bailard Inc.. Company insiders that have bought Aileron Therapeutics stock in the last two years include Muneer A Satter, Reinhard J Ambros, and Rickenbach Josef H Von.
View insider buying and selling activity for Aileron Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $0.44.

How much money does Aileron Therapeutics make?

Aileron Therapeutics has a market capitalization of $39.96 million. The company earns $-26.16 million in net income (profit) each year or ($0.300010) on an earnings per share basis.

How many employees does Aileron Therapeutics have?

Aileron Therapeutics employs 9 workers across the globe.

What is Aileron Therapeutics' official website?

The official website for Aileron Therapeutics is www.aileronrx.com.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at (617) 995-0900 or via email at [email protected].

This page was last updated on 5/21/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.